TWI857043B - 用於治療ｋｉｔ及ｐｄｇｆｒａ介導之疾病的組合物及方法 - Google Patents

用於治療ｋｉｔ及ｐｄｇｆｒａ介導之疾病的組合物及方法 Download PDF

Info

Publication number
TWI857043B
TWI857043B TW109111858A TW109111858A TWI857043B TW I857043 B TWI857043 B TW I857043B TW 109111858 A TW109111858 A TW 109111858A TW 109111858 A TW109111858 A TW 109111858A TW I857043 B TWI857043 B TW I857043B
Authority
TW
Taiwan
Prior art keywords
compound
mmol
compounds
pharmaceutically acceptable
kit
Prior art date
Application number
TW109111858A
Other languages
English (en)
Chinese (zh)
Other versions
TW202104231A (zh
Inventor
約瑟夫 Ｌ 金
湯瑪斯 Ａ 迪寧
提摩西 古齊
Original Assignee
美商纜圖藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70416596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI857043(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商纜圖藥品公司 filed Critical 美商纜圖藥品公司
Publication of TW202104231A publication Critical patent/TW202104231A/zh
Application granted granted Critical
Publication of TWI857043B publication Critical patent/TWI857043B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW109111858A 2019-04-12 2020-04-08 用於治療ｋｉｔ及ｐｄｇｆｒａ介導之疾病的組合物及方法 TWI857043B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US62/833,529 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US62/911,016 2019-10-04
US201962930240P 2019-11-04 2019-11-04
US62/930,240 2019-11-04

Publications (2)

Publication Number Publication Date
TW202104231A TW202104231A (zh) 2021-02-01
TWI857043B true TWI857043B (zh) 2024-10-01

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109111858A TWI857043B (zh) 2019-04-12 2020-04-08 用於治療ｋｉｔ及ｐｄｇｆｒａ介導之疾病的組合物及方法

Country Status (33)

Country Link
US (3) US12552795B2 (enExample)
EP (2) EP4424312A3 (enExample)
JP (2) JP7600140B2 (enExample)
KR (1) KR102875260B1 (enExample)
CN (1) CN113939515B (enExample)
AU (1) AU2020272743B2 (enExample)
BR (1) BR112021020441A2 (enExample)
CA (1) CA3136802A1 (enExample)
CL (1) CL2021002656A1 (enExample)
CO (1) CO2021015113A2 (enExample)
DK (1) DK3953357T3 (enExample)
EC (1) ECSP21080096A (enExample)
ES (1) ES2980811T3 (enExample)
FI (1) FI3953357T3 (enExample)
HR (1) HRP20240702T1 (enExample)
HU (1) HUE067299T2 (enExample)
IL (1) IL287168B2 (enExample)
LT (1) LT3953357T (enExample)
MA (1) MA55604B1 (enExample)
MD (1) MD3953357T2 (enExample)
MX (1) MX2021012469A (enExample)
MY (1) MY209048A (enExample)
PE (1) PE20212331A1 (enExample)
PH (1) PH12021552568A1 (enExample)
PL (1) PL3953357T3 (enExample)
PT (1) PT3953357T (enExample)
RS (1) RS65644B1 (enExample)
SG (1) SG11202111244XA (enExample)
SI (1) SI3953357T1 (enExample)
SM (1) SMT202400229T1 (enExample)
TW (1) TWI857043B (enExample)
WO (1) WO2020210293A1 (enExample)
ZA (1) ZA202108104B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970745B (zh) 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
SG11202111244XA (en) 2019-04-12 2021-11-29 Blueprint Medicines Corp Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
CN117098760B (zh) * 2020-10-14 2026-04-14 缆图药品公司 用于治疗kit和pdgfra介导的疾病的组合物和方法
WO2022081626A1 (en) * 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
JP7763848B2 (ja) * 2021-03-03 2025-11-04 ブループリント メディシンズ コーポレイション Ｋｉｔ－およびｐｄｇｆｒａ－媒介性疾患を治療するための化合物を製造するための合成方法および中間生成物
WO2022192558A1 (en) 2021-03-10 2022-09-15 Blueprint Medicines Corporation Salt and solid forms of a kinase inhibitor
CN117794935A (zh) * 2021-03-10 2024-03-29 缆图药品公司 激酶抑制剂的盐和固体形式
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
US20250129067A1 (en) * 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2024171143A1 (en) 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Salts and solid forms of elenestinib

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057873A1 (en) * 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2018183712A1 (en) * 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
IL144977A0 (en) * 1999-05-21 2002-06-30 Bristol Myers Squibb Co Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
MXPA02003436A (es) 1999-10-07 2002-08-20 Amgen Inc Inhibidores de triazina cinasa.
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
PL219736B1 (pl) 2002-04-23 2015-07-31 Bristol Myers Squibb Co Pochodna pirolotriazynoaniliny, kompozycja farmaceutyczna i jej zastosowanie
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
UA81453C2 (en) 2003-02-27 2008-01-10 Pyrazolopyridine derivates
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
EP1755607A2 (en) 2004-04-29 2007-02-28 Pharmix Corporation Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
EP1945222B1 (en) 2005-11-02 2012-12-26 Bayer Pharma Aktiengesellschaft Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PL1973910T3 (pl) 2006-01-27 2013-11-29 Shanghai hengrui pharmaceutical co ltd Pirolo[3,2-c]pirydyn-4-onowo-2-indolinonowe inhibitory kinazy białkowej
SI2041138T1 (sl) 2006-07-07 2014-08-29 Bristol-Myers Squibb Company Pirolotriazin kinazni inhibitorji
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
AU2009226024B2 (en) 2008-03-20 2012-07-12 Amgen Inc. Aurora kinase modulators and method of use
WO2010022055A2 (en) 2008-08-20 2010-02-25 Amgen Inc. Inhibitors of voltage-gated sodium channels
CA2764818A1 (en) 2009-06-08 2010-12-16 California Capital Equity, Llc Triazine derivatives and their therapeutical applications
CA2767008C (en) 2009-07-07 2018-01-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
AU2011218167B2 (en) 2010-02-17 2014-07-10 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
WO2012027495A1 (en) 2010-08-27 2012-03-01 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
WO2013004551A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
JP6318156B2 (ja) 2012-09-06 2018-04-25 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼをモジュレートするための化合物および方法、ならびにその指標
ME03000B (me) 2012-12-21 2018-10-20 Plexxikon Inc Jedinjenja i metode modulacije kinaze i povezane indikacije
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
CN109970745B (zh) 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途
CR20200588A (es) 2018-05-04 2021-06-24 Inflazome Ltd Compuestos novedosos
WO2020102095A1 (en) 2018-11-12 2020-05-22 Blueprint Medicines Corporation Avapritinib resistance of kit mutants
PE20211756A1 (es) 2018-12-20 2021-09-07 Pfizer FORMAS POLIMORFICAS NOVEDOSAS DE UN INHIBIDOR DE TGFß
SG11202111244XA (en) 2019-04-12 2021-11-29 Blueprint Medicines Corp Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
WO2022081626A1 (en) 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions and methods for treating kit-and pdgfra-mediated diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057873A1 (en) * 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2018183712A1 (en) * 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr

Also Published As

Publication number Publication date
US20260138986A1 (en) 2026-05-21
CN113939515A (zh) 2022-01-14
SMT202400229T1 (it) 2024-07-09
WO2020210293A1 (en) 2020-10-15
FI3953357T3 (fi) 2024-07-15
CL2021002656A1 (es) 2022-08-26
CA3136802A1 (en) 2020-10-15
HUE067299T2 (hu) 2024-10-28
MY209048A (en) 2025-06-18
EP3953357A1 (en) 2022-02-16
KR102875260B1 (ko) 2025-10-23
EP4424312A2 (en) 2024-09-04
US20220153748A1 (en) 2022-05-19
IL287168B1 (en) 2025-06-01
RS65644B1 (sr) 2024-07-31
AU2020272743A1 (en) 2021-11-11
HRP20240702T1 (hr) 2024-08-16
PE20212331A1 (es) 2021-12-14
PH12021552568A1 (en) 2022-07-04
TW202104231A (zh) 2021-02-01
CN113939515B (zh) 2024-06-18
IL287168B2 (en) 2025-10-01
ZA202108104B (en) 2024-02-28
MD3953357T2 (ro) 2024-09-30
MA55604B1 (fr) 2024-08-30
KR20220025704A (ko) 2022-03-03
JP2025029094A (ja) 2025-03-05
EP4424312A3 (en) 2025-01-08
BR112021020441A2 (pt) 2021-12-14
US10829493B2 (en) 2020-11-10
PL3953357T3 (pl) 2024-09-02
US20200325141A1 (en) 2020-10-15
US12552795B2 (en) 2026-02-17
MA55604A (fr) 2022-02-16
LT3953357T (lt) 2024-07-25
EP3953357B1 (en) 2024-04-17
SG11202111244XA (en) 2021-11-29
JP2022526850A (ja) 2022-05-26
DK3953357T3 (en) 2024-06-10
SI3953357T1 (sl) 2024-08-30
IL287168A (en) 2021-12-01
CO2021015113A2 (es) 2022-02-28
ES2980811T3 (es) 2024-10-03
JP7600140B2 (ja) 2024-12-16
AU2020272743B2 (en) 2025-10-16
ECSP21080096A (es) 2022-02-25
PT3953357T (pt) 2024-07-24
MX2021012469A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
JP7600140B2 (ja) Ｋｉｔ及びｐｄｇｆｒａ媒介性疾患を治療するための組成物及び方法
EP4667458A1 (en) Pharmaceutical composition for treatment of cancer, comprising sos1 inhibitor and anticancer drug
TWI418554B (zh) 結晶形（ｒ）－（ｅ）－２－（４－（２－（５－（１－（３，５－二氯吡啶－４－基）乙氧基）－１ｈ－吲唑－３－基）乙烯基）－１ｈ－吡唑－１－基）乙醇
EP3746072B1 (en) 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof
WO2018191587A1 (en) Tam kinase inhibitors
CN115141202A (zh) 嘧啶并吡嗪酮化合物及其用途
CN117098760B (zh) 用于治疗kit和pdgfra介导的疾病的组合物和方法
RU2817354C2 (ru) Композиции и способы лечения kit- и pdgfra-опосредованных заболеваний
US20230391780A1 (en) Compositions and methods for treating kit- and pdgfra-mediated diseases
CN107840847A (zh) 氘代3‑(4,5‑取代氨基嘧啶)苯基衍生物及其应用
HK40071629B (en) Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
HK40071629A (en) Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
HK40018820A (en) Egfr inhibitor, and preparation and application thereof
HK1207374B (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors
HK1207374A1 (en) Imidazo[1,2-b]pyridazine derivatives as kinase inhibitors